Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged
NEW YORK, Aug. 25, 2024 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Syros Pharmaceuticals, Inc. ("Syros" or "the Company") (NASDAQ: SYRS). Investors who purchased Syros securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/SYRS.
Bronstein, Gewirtz & Grossman, LLC正在调查购买Syros Pharmaceuticals, Inc.（"Syros"或"the Company"）（纳斯达克：SYRS）股票的潜在索赔。鼓励购买Syros证券的投资者获取更多信息并协助调查，请访问该公司的网站：bgandg.com/SYRS。
Investigation Details
调查详情
On August 12, 2024, Syros issued a press release "announcing that it will discontinue enrollment in the SELECT-AML-1 Phase 2 clinical trial evaluating the triplet regimen of tamibarotene in combination with venetoclax and azacitidine compared to the doublet regimen of venetoclax and azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia (AML) and RARA gene overexpression." According to the Company, the "decision is based on the results of a prespecified interim analysis of the trial," and its analysis that "the probability for success . . . to demonstrate superiority at the final analysis . . . was considered low."
2024年8月12日，Syros发表新闻稿"宣布将停止SELECt-AML-1第2期临床试验，评估tamibarotene与venetoclax和azacitidine三联方案与venetoclax和azacitidine双联方案在新诊断、不适合的急性髓系白血病（AML）和RARA基因过度表达患者中的疗效。"据公司称，"此决定基于试验的预先规定中期分析的结果"，并且其分析认为"在最终分析中展示卓越性的成功概率考虑较低。"
What's Next?
下一步是什么？
If you are aware of any facts relating to this investigation or purchased Syros securities, you can assist this investigation by visiting the firm's site: bgandg.com/SYRS. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
如果您了解与此调查相关的任何事实或购买了Syros证券，您可以通过访问该公司的网站bgandg.com/SYRS来协助此调查。您还可以联系Bronstein，Gewirtz和Grossman，LLC的Peretz Bronstein或其客户关系经理Nathan Miller：332-239-2660。
There is No Cost to You
您不需要支付任何费用
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
我们代表投资者进行集体诉讼，按照诉讼结果收取费用基础。这意味着我们将要求法院偿还我们的实际支出和律师费，通常是总赔偿的一定比例，仅在我们成功时。
Why Bronstein, Gewirtz & Grossman
为什么选择Bronstein，Gewirtz＆Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Bronstein，Gewirtz和Grossman，LLC是一家国际知名的公司，代表投资者进行证券欺诈集体诉讼和股东衍生诉讼。我们的公司已经为全国投资者赢回了数亿美元。
Attorney advertising. Prior results do not guarantee similar outcomes.
律师广告。以前的结果不能保证相似的结果。
Contact
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | [email protected]
联系人
Bronstein，Gewirtz＆Grossman，LLC
Peretz Bronstein或Nathan Miller
332-239-2660 | [email protected]
SOURCE Bronstein, Gewirtz & Grossman, LLC
资料来源：Bronstein，Gewirtz＆Grossman，LLC